

# The impact of psoriasis on the lifequality: a cohort of 140 Moroccan patients

Awatef Kelati<sup>1</sup>, Mariame Meziane<sup>1</sup>, Mounir Jaafari<sup>2</sup>, Fatima Zahra Mernissi<sup>1</sup>

<sup>1</sup>Department of Dermatology, Hospital Hassan II of Fez, Fez, Morocco, <sup>2</sup>Department of Psychiatry, Hospital Hassan II of Fez, Fez, Morocco

Corresponding author: Dr. Awatef Kelati, E-mail: awatkelati@gmail.com

#### ABSTRACT

Introduction: The alteration of the life quality in psoriasis is currently proved. Aim: To evaluate the particularity of this impact in Moroccan psoriatic population. Methods: It was a prospective cohort of 140 psoriatic patients who filled the 16-Skindex questionnary to evaluate this alteration of the life quality. Results: The life quality was significantly affected in patients having severe or old psoriasis and in young females, also it was related to the low Socioeconomic level and the living in rural areas, to the presence of psoriatic arthritis, to the scalp, the nails and mucosal involvement and to the use of systemic treatments. However, the emotional life, theimpact on daily activities and the sleep quality were not affected in our population. Conclusions: we had a low negative impact on the sleep quality and the emotional life which may be explained by the role of the family support in our society.

Keys words: Psoriasis; quality of life; Prospective cohort study

#### INTRODUCTION

The Psoriasis is an inflammatory, systemic and multifactorial skin disease affecting about 2% of the Moroccan population [1]. It is considered as an autoimmune disease with abnormality of mitosis and differentiation of keratinocytes where the cyclic nucleotide and lipid mediators play a key role [2,3].

This systemic disease is also known linked to a great number of comorbidities especially metabolic [4] and psychiatric [5] ones.

The alteration of the life quality of psoriatic patients has been shown in many epidemiological studies in adults and in children [6-14]. So the aim of our study was to evaluate this psycho-social impact of psoriasis in Moroccan psoriatic patients.

## **MATERIALS AND METHODS**

It was a descriptive, analytical, unicentric and prospective study of 140 psoriatic patients treated

in the Department of Dermatology of the Hospital Hassan II of Fez, during a period of 1 year: 2013/2014. Epidemiological and clinical data were collected in the psoriasis consultation by our doctors of the Department of Dermatology.

Psoriasis severity was calculated based on the Psoriasis Area Severity Index (PASI): Mild psoriasis: PASI <7, Moderate psoriasis: PASI between 8 and 12 and Severe psoriasis: PASI> 12.

we used the 16-Skindex as a questionnary for the evaluation of the impact of psoriasis on the life quality of psoriatic patients which include several items: pruritus, psychological impact: "No improving and recidivism, fear of worsening or persisting lesions or scars, frustration, shame, depression and anger ", relationships with others and the integrity in society, Emotional life, impact on daily activities and hobbies.

We estimated that a low impact on the life quality is a score of Skindex<10, a moderate impact on the

How to cite this article: Kelati A, Meziane M, Jaafari M, Mernissi FZ. The impact of psoriasis on the lifequality: a cohort of 140 Moroccan patients. Our Dermatol Online. 2016;7(1):10-16.

**Submission:** 17.07.2015; **Acceptance:** 09.09.2015

DOI:10.7241/ourd.20161.3

life quality if the Skindexis between 10 and 50,and a significant impact on the life quality if the Skindex> 50.

Data analysis was performed using the SPSS 20 software, 2 kinds of analysis were carried out: Descriptive and univariate analysis.

In the univariate analysis: we analyzed the epidemiological and clinical data significantly related to each item of the Skindex.

# **RESULTS**

We collected 140 patients with psoriasis for this study, the mean age was 30.5 years.

58.9% of our patients were young (between 15 years and 45 years old) and we had a slight male predominance (51%). Our patients had a moderate socioeconomic level in 55.5% of cases and 50,4% of them had a recent psoriasis.

Plaque psoriasis was the most frequent form (80,5%) and we had a scalp involvement in 74.1 % of cases. 51,8% of patients had a mild psoriasis while 31.4 % had a severe one.

Besides, severe itching was present in 31,9% of our patients and 26,8% of patients had moderate pruritus.

Furthermore, 50% of our patients had an important impact on the life quality, 35% had a moderate impact and 15% of patients had a low impact on the life quality.

Concerning the treatments used in our patients: 74.5 % of patients used topical treatments, 24.8 % used systemic treatments (30 patients: methotrexate, 2 patients: Infliximab (Remicade) for Psoriatic arthritis, 2 patients: Retinoids), and 26.6% of patients used phototherapy UVB TL01 (Table. I).

# In the Univariate Analysis

The characteristics of psoriasis significantly related to the Pruritus in our population study were: the low SEL (p=0.05), the Mild psoriasis (p=0.011) and the living in rural areas (p=0.05) while the No improving and recidivism was significantly associated with Young age (p=0.000), Female gender (p=0.000), Psoriatic arthritis (p=0.004) and Psoriasis of the scalp,the nails and mucosal psoriasis (p=0.000).

Table 1: Descriptive analysis

| Number of patients=140         N (%)           Demographic data         Age (years)           ≤ 15         4 (2.9)           15-45         82 (58.9)           > 45         52 (37.4)           Gender         Male         71 (51)           Female         67 (48.2)           Socio economiclevel         Low         51 (37.2)           Moderate         76 (55.5)         High         10 (7.3)           Cuttural level         None         17 (12.4)         Primary         33 (24.1)           Primary         33 (24.1)         Secondary         52 (38)         Academic         35 (25.5)         Origin           Rural         42 (30.7)         Urban         95 (69.3)         Duration of the disease (years)         ≤5         69 (50.4)         5-10         36 (26.3)         20         2(23.4)         Clinical Data         Type of psoriasis         12 (8.6)         Psoriaticarthritis         5 (36.6)         Psoriaticarthritis         5 (36.6)         Psoriaticarthritis         5 (36.6)         Psoriaticarthritis         5 (36.6)         Psoriatical psoriasis         12 (8.6)         Psoriatical psoriasis         1 (6.3)         Psoriatical psoriasis         1 (7.5)         In (7.5)         In (7.5)         In (7.5)         In (7.5)   | Table 1: Descriptive analysis     |            |
|--|-----------------------------------|------------|
| Age (years)       ≤ 15       4 (2.9)         15-45       82 (58.9)       > 45       52 (37.4)         Gender       Male       71 (51)       Female       67 (48.2)         Socio economiclevel   | Number of patients=140            | N (%)      |
| ≤15       4 (2.9)         15-45       82 (58.9)         > 45       52 (37.4)         Gender       Male       71 (51)         Female       67 (48.2)         Socio economiclevel       10 (7.3)         Low       51 (37.2)         Moderate       76 (55.5)         High       10 (7.3)         Cultural level       10 (7.3)         None       17 (12.4)         Primary       33 (24.1)         Secondary       52 (38)         Academic       35 (25.5)         Origin       42 (30.7)         Rural       42 (30.7)         Urban       95 (69.3)         Duration of the disease (years)       <5  | Demographic data                  |            |
| 15-45  | Age (years)                       |            |
| Sender   Male  | ≤15                               | 4 (2,9)    |
| Gender Male Female Female Socio economiclevel Low Jordinaria India (15,12) Moderate High Low Moderate None Primary None Female None Female None First (15,12) Moderate None First (15,12) None First (15,13) None First (15,14) None First (15,14 |                                   |            |
| Male       71 (51)         Female       67 (48,2)         Socio economiclevel       51 (37,2)         Low       51 (37,2)         Moderate       76 (55,5)         High       10 (7,3)         Cultural level       17 (12,4)         None       17 (12,4)         Primary       33 (24,1)         Secondary       52 (38)         Academic       35 (25,5)         Origin       95 (69,3)         Rural       42 (30,7)         Urban       95 (69,3)         Duration of the disease (years)       5         <5  |                                   | 52 (37,4)  |
| Female 67 (48,2) Socio economiclevel Low 51 (37,2) Moderate 76 (55,5) High 10 (7,3) Cultural level None 17 (12,4) Primary 33 (24,1) Secondary 52 (38) Academic 35 (25,5) Origin Rural 42 (30,7) Urban 95 (69,3) Duration of the disease (years) <5 69 (50,4) 5-10 36 (26,3) ≥10 32 (23,4) Clinical Data Type of psoriasis Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Psoriaticarthritis 5 (3,6) Psoriaticarthritis 5 (3,6) Psoriaticarthritis 5 (4,3) Particular locations of psoriasis Scalp 103 (74,1) mucosal psoriasis 1 (0,7) Nail psoriasis 1 (0,7) Sedween 10 and 30 23 (16,8) Between 10 and 30 29 (21,2) BSA >50 14 (10,2) BSA >50 14 (10,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 77 (56,8) The impact on the life quality Pruritus Intense 44 (31,9) Moderate Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Anger 64 (46,4) Emotionnal life 23 (16,7)   |                                   | /v         |
| Socio economiclevel  Low 51 (37,2)  Moderate 76 (55,5)  High 10 (7,3)  Cultural level  None 17 (12,4)  Primary 33 (24,1)  Secondary 52 (38)  Academic 35 (25,5)  Origin  Rural 42 (30,7)  Urban 95 (69,3)  Duration of the disease (years)   |                                   |            |
| Low 51 (37,2) Moderate 76 (55,5) High 10 (7,3)  Cultural level None 17 (12,4) Primary 33 (24,1) Secondary 52 (38) Academic 35 (25,5) Origin Rural 42 (30,7) Urban 95 (69,3) Duration of the disease (years) <5 69 (50,4) 5-10 36 (26,3) >10 32 (23,4)  Clinical Data Type of psoriasis Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Pustular psoriasis 12 (8,6) Psoriaticular locations of psoriasis Scalp 103 (74,1) mucosal psoriasis 7 (5) Inverse psoriasis 10 (0,7) Nail psoriasis 10 (0,7) Nail psoriasis 10 (0,7) Nail psoriasis 10 (23,3) Body surface area (BSA) (%) <10 71 (51,8) Between 10 and 30 23 (16,8) Between 30 and 50 29 (21,2) BSA >50 14 (10,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 77 (26,8) Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Emotionnal life 23 (16,7)   |                                   | 67 (48,2)  |
| Moderate       76 (55.5)         High       10 (7,3)         Cultural level       17 (12.4)         None       17 (12.4)         Primary       33 (24.1)         Secondary       52 (38)         Academic       35 (25.5)         Origin       18 (20.7)         Rural       42 (30.7)         Urban       95 (69.3)         Duration of the disease (years)       5         <5  |                                   | 51 (27.2)  |
| High   |                                   |            |
| Cultural level None 17 (12,4) Primary 33 (24,1) Secondary 52 (38) Academic 35 (25,5) Origin Rural 42 (30,7) Urban 95 (69,3) Duration of the disease (years) <5 69 (50,4) 5-10 36 (26,3) >10 32 (23,4) Clinical Data Type of psoriasis Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Psoriaticarthritis 5 (3,6) Psoriaticarthritis 5 (4,3) Particular locations of psoriasis Scalp 103 (74,1) mucosal psoriasis 1 (0,7) Nail psoriasis 1 (0,7) Nail psoriasis 1 (3,9) Body surface area (BSA) (%) <10 71 (51,8) Between 10 and 30 23 (16,8) Between 30 and 50 29 (21,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 97 (68,5) Moderate psoriasis 97 (68,5) Moderate psoriasis 97 (68,5) Moderate psoriasis 97 (68,5) Moderate Psoriosis 97 (26,8) Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Emotionnal life 23 (16,7)   |                                   |            |
| Primary 33 (24,1) Secondary 52 (38) Academic 35 (25,5) Origin Rural 42 (30,7) Urban 95 (69,3) Duration of the disease (years) <5 69 (50,4) 5-10 36 (26,3) >10 32 (23,4) Clinical Data Type of psoriasis Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Pustular psoriasis 3 (2,1) Erythrodermic psoriasis Scalp 103 (74,1) mucosal psoriasis 7 (5) Inverse psoriasis 10,0,7) Nail psoriasis 55 (39,5) Palmoplantar psoriasis 13 (9,3) Body surface area (BSA) (%) <10 71 (51,8) Between 10 and 30 23 (16,8) Between 30 and 50 29 (21,2) BSA >50 14 (10,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 97 (68,5) Moderate psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 77 (58,5) Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Anger 64 (46,4) Emotionnal life 23 (16,7)  |                                   | (. , . ,   |
| Primary       33 (24,1)         Secondary       52 (38)         Academic       35 (25,5)         Origin       42 (30,7)         Rural       42 (30,7)         Urban       95 (69,3)         Duration of the disease (years)       5 (69, 50, 4)         5-10       36 (26,3)         >10       32 (23,4)         Clinical Data       Type of psoriasis         Plaque       112 (80,5)         Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pustular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       7 (5)         Particular locations of psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       10         <10  |                                   | 17 (12,4)  |
| Academic 35 (25,5) Origin Rural 42 (30,7) Urban 95 (69,3) Duration of the disease (years) <5 69 (50,4) 5-10 36 (26,3) >10 32 (23,4) Clinical Data Type of psoriasis Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Pustular psoriasis 3 (2,1) Erythrodermic psoriasis 6 (4,3) Particular locations of psoriasis Scalp 103 (74,1) mucosal psoriasis 7 (5) Inverse psoriasis 10,07) Nail psoriasis 55 (39,5) Palmoplantar psoriasis 13 (9,3) Body surface area (BSA) (%) <10 71 (51,8) Between 10 and 30 23 (16,8) Between 30 and 50 29 (21,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Severe psoriasis 16 (12,6) Pruritus Intense 44 (31,9) Moderate 73 (53,3) Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Anger 64 (46,4) Emotionnal life 23 (16,7)   | Primary                           | 33 (24,1)  |
| Origin       42 (30,7)         Rural       42 (30,7)         Urban       95 (69,3)         Duration of the disease (years)       -5         ≤5       69 (50,4)         5-10       36 (26,3)         >10       32 (23,4)         Clinical Data       Type of psoriasis         Plaque       112 (80,5)         Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pastricular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       7 (5)         Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       <10  | Secondary                         | 52 (38)    |
| Rural       42 (30,7)         Urban       95 (69,3)         Duration of the disease (years)       -5         ≤5       69 (50,4)         5-10       36 (26,3)         >10       32 (23,4)         Clinical Data       Type of psoriasis         Plaque       112 (80,5)         Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pustular psoriasis       6 (4,3)         Particular locations of psoriasis       7 (5)         Particular locations of psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       10         <10  | Academic                          | 35 (25,5)  |
| Urban       95 (69,3)         Duration of the disease (years)       ≤5       69 (50,4)         5-10       36 (26,3)       >10       32 (23,4)         Clinical Data       Type of psoriasis         Plaque       112 (80,5)       Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)       Pustular psoriasis       6 (4,3)         Particular locations of psoriasis       6 (4,3)         Particular locations of psoriasis       7 (5)       103 (74,1)         mucosal psoriasis       7 (5)       1 (0,7)         Nail psoriasis       55 (39,5)       13 (9,3)         Body surface area (BSA) (%)       <10  | Origin                            |            |
| Duration of the disease (years)  <5 69 (50,4) 5-10 36 (26,3) >10 32 (23,4)  Clinical Data  Type of psoriasis  Plaque 112 (80,5) Guttate psoriasis 12 (8,6) Psoriaticarthritis 5 (3,6) Pustular psoriasis 6 (4,3)  Particular locations of psoriasis Scalp 103 (74,1) mucosal psoriasis 7 (5) Inverse psoriasis 10,7) Nail psoriasis 10,7) Nail psoriasis 55 (39,5) Palmoplantar psoriasis 13 (9,3) Body surface area (BSA) (%) <10 71 (51,8) Between 10 and 30 23 (16,8) Between 30 and 50 29 (21,2) BSA >50 14 (10,2) PASI Mild psoriasis 87 (68,5) Moderate psoriasis 16 (12,6) Severe psoriasis 24 (18,9) The impact on the life quality Pruritus Intense 44 (31,9) Moderate Psychological impact No improving and recidivism 65 (46,7) Fear of worsening or persisting lesions or scars 73 (53,3) Frustration 41 (41,3) Shame 51 (37,2) Depression 59 (42,8) Anger 64 (46,4) Emotionnal life 23 (16,7)   | Rural                             | 42 (30,7)  |
| <5   |                                   | 95 (69,3)  |
| 5-10 36 (26,3) > 10 32 (23,4)  Clinical Data  Type of psoriasis  Plaque 112 (80,5)  Guttate psoriasis 12 (8,6)  Psoriaticarthritis 5 (3,6)  Pustular psoriasis 3 (2,1)  Erythrodermic psoriasis 6 (4,3)  Particular locations of psoriasis  Scalp 103 (74,1)  mucosal psoriasis 7 (5)  Inverse psoriasis 10,0,7)  Nail psoriasis 55 (39,5)  Palmoplantar psoriasis 13 (9,3)  Body surface area (BSA) (%)  <10 71 (51,8)  Between 10 and 30 23 (16,8)  Between 30 and 50 29 (21,2)  BSA > 50 14 (10,2)  PASI  Mild psoriasis 87 (68,5)  Moderate psoriasis 16 (12,6)  Severe psoriasis 65 (46,7)  Fear of worsening or persisting lesions or scars 73 (53,3)  Frustration 41 (41,3)  Shame 51 (37,2)  Depression 59 (42,8)  Anger 64 (46,4)  Emotionnal life 23 (16,7)  |                                   |            |
| Signature   Sign   |                                   |            |
| Clinical Data Type of psoriasis  Plaque  |                                   |            |
| Type of psoriasis       112 (80,5)         Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pustular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       5 (30,5)         Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         8d etween 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       87 (68,5)         Moderate psoriasis       24 (18,9)         The impact on the life quality       7         Pruritus       11 (11,2)         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)   |                                   | 32 (23,4)  |
| Plaque       112 (80,5)         Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pustular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       5 (30,5)         Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         Between 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       87 (68,5)         Moderate psoriasis       24 (18,9)         The impact on the life quality       70         Pruritus       11 (10,2)         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       70 (5)         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame  |                                   |            |
| Guttate psoriasis       12 (8,6)         Psoriaticarthritis       5 (3,6)         Pustular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       103 (74,1)         Mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         Between 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       Mild psoriasis       87 (68,5)         Moderate psoriasis       24 (18,9)         The impact on the life quality       7         Pruritus       1ntense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       85 (46,7)         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7) </td <td></td> <td>112 (80.5)</td>   |                                   | 112 (80.5) |
| Psoriaticarthritis       5 (3,6)         Pustular psoriasis       3 (2,1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       103 (74,1)         Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       -10         <10   |                                   |            |
| Pustular psoriasis       3 (2.1)         Erythrodermic psoriasis       6 (4,3)         Particular locations of psoriasis       103 (74,1)         Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       -10         < 10   |                                   |            |
| Particular locations of psoriasis       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         Between 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       87 (68,5)         Moderate psoriasis       24 (18,9)         The impact on the life quality       9         Pruritus       Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   | Pustular psoriasis                |            |
| Scalp       103 (74,1)         mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       -10         <10  | Erythrodermic psoriasis           | 6 (4,3)    |
| mucosal psoriasis       7 (5)         Inverse psoriasis       1 (0,7)         Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         Setween 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality       7         Pruritus       Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  | Particular locations of psoriasis |            |
| Inverse psoriasis 1 (0,7)  Nail psoriasis 55 (39,5)  Palmoplantar psoriasis 13 (9,3)  Body surface area (BSA) (%)  <10 71 (51,8)  Between 10 and 30 23 (16,8)  Between 30 and 50 29 (21,2)  BSA >50 14 (10,2)  PASI  Mild psoriasis 87 (68,5)  Moderate psoriasis 16 (12,6)  Severe psoriasis 24 (18,9)  The impact on the life quality  Pruritus  Intense 44 (31,9)  Moderate No improving and recidivism 65 (46,7)  Fear of worsening or persisting lesions or scars 73 (53,3)  Frustration 41 (41,3)  Shame 51 (37,2)  Depression 59 (42,8)  Anger 64 (46,4)  Emotionnal life 23 (16,7)   | Scalp                             | 103 (74,1) |
| Nail psoriasis       55 (39,5)         Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         <10   | mucosal psoriasis                 | 7 (5)      |
| Palmoplantar psoriasis       13 (9,3)         Body surface area (BSA) (%)       71 (51,8)         etween 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality         Pruritus       1ntense         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  |                                   |            |
| Body surface area (BSA) (%)  <10 71 (51,8)  Between 10 and 30 23 (16,8)  Between 30 and 50 29 (21,2)  BSA >50 14 (10,2)  PASI  Mild psoriasis 87 (68,5)  Moderate psoriasis 16 (12,6)  Severe psoriasis 24 (18,9)  The impact on the life quality  Pruritus  Intense 44 (31,9)  Moderate 9x (26,8)  Psychological impact  No improving and recidivism 65 (46,7)  Fear of worsening or persisting lesions or scars 73 (53,3)  Frustration 41 (41,3)  Shame 51 (37,2)  Depression 59 (42,8)  Anger 64 (46,4)  Emotionnal life 23 (16,7)  |                                   |            |
| <10  |                                   | 13 (9,3)   |
| Between 10 and 30       23 (16,8)         Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality       17 (26,8)         Pruritus       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   | 71 /E1 0\  |
| Between 30 and 50       29 (21,2)         BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality       7         Pruritus       1         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   | 22 (42.2)  |
| BSA >50       14 (10,2)         PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality       7         Pruritus       44 (31,9)         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| PASI       87 (68,5)         Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality       24 (18,9)         Pruritus       44 (31,9)         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| Moderate psoriasis       16 (12,6)         Severe psoriasis       24 (18,9)         The impact on the life quality         Pruritus       44 (31,9)         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  |                                   | (12,2)     |
| Severe psoriasis       24 (18,9)         The impact on the life quality         Pruritus         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   | Mild psoriasis                    | 87 (68,5)  |
| The impact on the life quality         Pruritus         Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  | Moderate psoriasis                | 16 (12,6)  |
| Pruritus         44 (31,9)           Intense         44 (31,9)           Moderate         37 (26,8)           Psychological impact         65 (46,7)           No improving and recidivism         65 (46,7)           Fear of worsening or persisting lesions or scars         73 (53,3)           Frustration         41 (41,3)           Shame         51 (37,2)           Depression         59 (42,8)           Anger         64 (46,4)           Emotionnal life         23 (16,7)   | Severe psoriasis                  | 24 (18,9)  |
| Intense       44 (31,9)         Moderate       37 (26,8)         Psychological impact       65 (46,7)         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  | The impact on the life quality    |            |
| Moderate       37 (26,8)         Psychological impact       65 (46,7)         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  | Pruritus                          |            |
| Psychological impact       65 (46,7)         No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| No improving and recidivism       65 (46,7)         Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  |                                   | 37 (26,8)  |
| Fear of worsening or persisting lesions or scars       73 (53,3)         Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)  |                                   | 05 (40 =)  |
| Frustration       41 (41,3)         Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| Shame       51 (37,2)         Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| Depression       59 (42,8)         Anger       64 (46,4)         Emotionnal life       23 (16,7)   |                                   |            |
| Anger 64 (46,4)<br>Emotionnal life 23 (16,7)   |                                   |            |
| Emotionnal life 23 (16,7)  | •                                 |            |
|  |                                   |            |
|  |                                   | (,,,       |
| Relationships with others 30 (21,7)  |                                   | 30 (21,7)  |

Cond.. **11** 

Table 1: (Continued...)

| Number of nations 140                  | NI /0/ \   |
|--|------------|
| Number of patients=140                 | N (%)      |
| Desire to beaccompanied                | 31 (22,6)  |
| Impact on daily activities and hobbies |            |
| Daily activities and quality of sleep  | 38 (27,7)  |
| Hobbies                                | 31 (22,5)  |
| Total skindex                          |            |
| Low impact on the life quality         | 21 (15)    |
| Moderate impact on the life quality    | 49 (35)    |
| Important impact on the life quality   | 70 (50)    |
| Treatements                            |            |
| Topicaltreatment                       | 102 (74,5) |
| Systemictreatment                      | 34 (24,8)  |
| Phototherapy                           | 37 (26,6)  |

The Fear of worsening or persisting lesions or scars was more frequent in women (p=0,05) and the Shame was significantly related to the Young age (p=0,02) and Severe psoriasis (p=0,006). Anger was significantly related to severe psoriasis (p=0,013), old one (0,07) and the use of systemic treatments (p=0,046).

Besides, Relationships with others was altered in female patients (p=0,041), young patients (p=0,019) and patients having Severe psoriasis (p=0,056), and generally, the quality of life was significantly altered in patients having severe psoriasis (p=0,016) and old psoriasis (p=0,009).

However, the following items were not significantly affected or related to a particular characteristics of psoriasis: the frustration, the emotional life, the desire to be accompanied, the impact on daily activities, the sleep quality and Hobbies (Table. II).

## DISCUSSION

Psoriasis is a complex multifactorial skin disease which is known linked to manymetabolic [15], autoimmune and psychiatric [10] comorbidities that must be taken into account in the management of this disease [16].

The psychological impact of psoriasis and the alteration of the life quality iscurrently proven in many studies, There are even some series that have proven that this negative impact is stronger than other chronic dermatitis such as atopic dermatitis [17], and that this impact of psoriasis is similar to other dangerous diseases such as breast cancer and certain serious heart diseases [18]. Other studies proposed a theory that this alteration of the life quality is compounded by the other comorbidities of psoriasis. Furthermore, a recent study

Table 2: Univariate analysis

| The skindex items           | Characteristics of psoriatic patients significantly associated with the item affected | P value |
|-----------------------------|---|---------|
| Pruritus                    | Low SEL   | 0,05    |
|                             | Mild psoriasis  | 0,011   |
|                             | Originfrom rural regions  | 0,05    |
| No improving and            | Young age   | 0,000   |
| recidivism                  | Female  | 0,000   |
|                             | Psoriaticarthritis  | 0,004   |
|                             | Psoriasis of the scalp, the nails   | 0,000   |
|                             | and mucosal psoriasis   |         |
| Fear of worsening or        | Female  | 0,005   |
| persisting lesions or scars |   |         |
| Shame                       | Young age   | 0,02    |
|                             | Severe psoriasis  | 0,006   |
| Depression                  | BSA >30%  | 0,026   |
| Anger                       | Severe psoriasis and BSA >30%   | 0,013   |
|                             | Old psoriasis   | 0,007   |
|                             | Systemictreatment   | 0,046   |
| Relationshipswithothers     | Young age   | 0,019   |
|                             | Female  | 0,041   |
|                             | BSA >30%  | 0,056   |
| Total skindex               | Severe psoriasis and BSA >30%   | 0,01    |
|                             | Old psoriasis   | 0,009   |

proved that this alteration of the quality of life affects not only psoriatic patients but also their families [19].

In our study, we aimed to evaluate this alteration of the life quality in Moroccan patients, we didn't study the life quality on psoriatic patients families, or the relationship of this impact and comorbidities. So we noticed that the Severity and theduration of psoriasis are the two characteristics significantly related to the general alteration of the life quality which is almost the same for other studies (resumed in Table III).

This impact is also increased by the scalp and nails involvement which affects the general health, emotional life, and increase the severity of psoriasis [20-22]. In our psoriatic patients, the scalp and nail involvement were significantly related to the fear of recurrence and persistence of lesions which may be explained by the fact that these areas of the body are the symbol of beauty especially in women.

Besides, there is currently a great interest in the psoriatic arthritis (PSA) and his negative impact on the life quality, especially if it complicates skin psoriasis, So several scales for assessing the quality of life of these patients were validated [23,24].

Furthermore, many studies proved the alteration of the life quality in patients with PSA than patients

Table 3: Review of literature

| Study                                   | Year          | Number of patients | Method of measurement   | Results  |
|---|---------------|--------------------|---|--|
| Taiwanese <sup>[28]</sup>               | 2011          | 480                | Dermatology life quality index (DLQI)                           | The psoriasis severity and the young age have a negative impact on quality of life                                       |
| Chilean <sup>[29]</sup>                 | 2011          | 153                | Skindex 29  | Important impact in males , young age , recent psoriasis, facial involvement   |
| Japanese <sup>[30]</sup>                | 2012          | 213                | Questionnary (total work and productivity impairment)           | The severity of psoriasis has an impact on work and productivity   |
| American <sup>[31]</sup>                | 2012          | 5604               |   | The severity of psoriasis increases the feeling of anger, frustration, embarrassment, pruritus and pain                  |
| Spanish (Pso life study) <sup>[5]</sup> | 2013          | 304                | Dermatology life quality index (DLQI)                           | Impact parallel to the severity of psoriasis and the involvement of uncovered areas                                      |
| Polish <sup>[32]</sup>                  | 2013          | 100                | Satisfaction with life scale                                    | The importance of satisfaction level increases with age  |
| Polish <sup>[33]</sup>                  | 2013          | 168                | Skindex 29  | Important Impact parallel to the severity of psoriasis, young age, somatic symptoms and disease acceptance               |
| Iranian <sup>[34]</sup>                 | 2014          | 55                 | Questionnary (social functioning (SF)-36)                       | alteration of the well-being and the quality of work   |
| Spanish (Arizona study)[35]             | 2014          | 1022               | DLQI, Short form 36 questionnary                                | Alteration of quality of life in females with sleep disorders, depression, anxiety                                       |
| Malaysian <sup>[36]</sup>               | 2013          | 250                | (DLQI) and Version 2 of the 12-Item<br>Short-Form Health Survey | The severity of psoriasis and the young age have a negative impact on quality of life with increased health care costs   |
| Our study                               | 2013/<br>2014 | 139                | Skindex 16  | The severity, duration of psoriasis, young age, female gender, low CL and SEL have a negative impact on the life quality |

with cutaneous psoriasis only [25,26], except one study which noticed that there was no change in the impairment of the quality of life with the presence of PSA in patients with cutaneous psoriasis using the PSAQOL questionnary [27]. In our study, we had a small sample of PSA with skin psoriasis (5 patients) because these patients are also followed by Rheumatologists especially those without skin psoriasis. Despite this fact, we proved that it affected significantly the life quality of our patients especially the fear of no improving and recidivism.

## **Pruritus**

Psoriasis is known among the most pruritic inflammatory dermatoses according to the results of several studies [37-41]. Furthermore, this pruritus increases the negative impact of psoriasis on the life quality such as sleep disorders, sexual, appetite and concentration troubles and the alteration of the quality of work [42-44].

In our study, Pruritus was present in 58,7% of our patients and was intense in 31,9%. It was significantly related to the Lower SEL, the origin from rural regions of and it increases the severity of psoriasis.

## **Depression**

If psychiatric comorbidity is important in psoriasis, depression is by far the most common psychiatric illness encountered [45-47]. The links between psoriasis and

depression are not only psychopathological, biological factors may explain this association (elevated levels of substance P and TNF, decreased serotonin levels) [48]. There is thus a vicious circle "psoriasis- alteration of the life quality- depression" which may further complicate the management of psoriasis, because the treatment of psoriasis doesn't improve necessarily the depression. On the contrary, it is obvious that depressed psoriatic patient could not treat correctly his psoriasis [49].

A UK population-based cohort study of 146,042 patients [50] demonstrated an increased incidence of diagnoses of depression, anxiety and suicidality in psoriasis; the authors estimated that over 10400 diagnoses of depression, 7100 diagnoses of anxiety, and 350 diagnoses of suicidality were attributable to psoriasis each year, while Gupta [51] found that 5.5% of patients with psoriasis had active suicidal ideation and that 9.5% expressed a death wish and that this depression is increased by the pruritus. Another study demonstrated an increased use of antidepressant drugs in psoriasis [52].

In our study, Depression was significantly observed in patients with severe psoriasis and fortunately we had no cases of suicidality.

# **Sleep Quality**

the sleep quality is among the domains the most affected in patients with psoriasis and this Sleep disturbances can cause significant quality of life impairment, which

was proved in many studies (koo and al [53]; Delfino and al [54]; Hu and al [55]. This sleep impairment in psoriasis is known linked to many reasons such as the pruritus, the psychological burden and the obstructive sleep apnea which is a common and an increasingly prevalent sleep disorder that is receiving attention in terms of a potential association with psoriasis, psoriatic arthritis and rheumatoid arthritis [56].

In our study, this sleep quality was not significantly affected, maybe because of spiritual and religious reasons and the role of the family support in our society.

## **Relationships and Social Integrity**

Human kind is known very sociable, but this sociability could be injured in some situations that makes the person want to be alone and distant from others. This situation could be in some chronic diseases like psoriasis. In the same time, psoriasis may attract attention and cause avoidance and public rejection which may cause a disturbance in the social integrity in psoriatic patients.

This social integrity disturbance is proven in some epidemiological studies [57,58] like the survey of Poot [59] that found severe family dysfunction in these patients in comparison with families without a psoriasis. Even in our study, we noticed an alteration of relationships with others especially in young female patients and patients with severe psoriasis with a significant persistence of the desire to be accompanied.

The psoriasis affects also sexual functioning. In Gupta's cross –sectional survey [60] of 120 inpatients, 40% reported a decline in sexual activity since the onset of psoriasis. Another survey of Sampogna and al [61] proved this sexual dysfunctioning.

In our study the sexual life has not been well exploited but psoriasis did not influence significantly the emotional life of our patients.

#### **Anger**

Anger is also among the most psychological troubles that we can observe in chronic diseases, unfortunately, it's association with psoriasis has not been well described.

In an Indian recent study [62] of 48 psoriatic patients, the prevalence of anger was estimated: 58.3%, and in

another American study, the prevalence of anger was more important: 89% [63].

In our study, we had a low prevalence of anger in comparison with others which may be explained by the religious convictions of our patients.

However, anger was significantly related to severe and old psoriasis and the use of systemic treatments in our patients.

Othersitems: like the fear of no improving and recidivism; the fear of worsening or persisting lesions or scars and the shame were items proved related to psoriasis in our population but were not described in other publications according to our knowledge.

Besides, the frustration and the desir to be accompanied were not related to psoriasis in our population and it were not described enough in the literature since there is just one descriptive American study of 75000 patients that reported the frustration in 89% of psoriatic patients [63].

#### CONCLUSION

In our study, Severe and old psoriasis causes an important impact on the life quality especially in young females which leads us to insist on the psychiatric approach of these patients to complete the global management of this chronic disease by the realization of a team work containing a psychologist in the special consultation of psoriasis patients.

# **Statement of Human and Animal Rights**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

#### Statement of Informed Consent

Informed consent was obtained from all patients for being included in the study.

## REFERENCES

- Ouahidi FE, Hocar O, Akhdari N, Amal S. Formes graves du psoriasis: étude rétrospective de 42 cas. Ann Dermatol Vénéréol. 2013;140(Suppl 1):S83
- 2. Azfar RS, Gelfand JM. Le psoriasis et les maladies métaboliques:

- épidémiologie et physiopathologie. Current Opinion in Rheumatology, vol.Curr Opin Rheumatol. 2008;20, no.204, pp. 416 4 22, 2008:416-22.
- Denis J. Psoriasis as a chronic inflammatory syndrome. Ann Dermatol Venerol. 2008;135:S296-S300.
- Zindancı I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of Metabolic Syndrome in Patients with Psoriasis. Scient World J. 2012;312463:1-5.
- Dauden E, Herrera E. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. Actas Dermosifiliogr. 2013;104:685-93.
- Eskin M, Savk E. Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis. J Eur Acad Dermatol Venerol. 2014;28:1553-9.
- Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92:258-63.
- Ekelund M, Mallbris L. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis. Acta Dermvenereol. 2013;93:684-8.
- 9. Tang MM, Chang CC. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol. 2013;52:314-22.
- Rabin F, Bhuiyan SI. Psychiatric and psychological comorbidities in patients with psoriasis- a review. Mymensingh Med J. 2012;21:780-6.
- Böhm D, Stock S. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol. 2013;27:220-6.
- Varnj JW, Globe DR. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171:485-92.
- Ganemo A, Wahlgren CF. Quality of life and clinical features in Swedish children with psoriasis. Pediatrdermatol. 2011;28:375-9.
- Basavaraj KH, Navya MA. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50:783-92.
- Shapiro J, Cohen AD, Weitzman D, Roy T, Michael D. psoriasis and cardiovascular risk factors: a case control study on inpatients comparing psoriasis to dermatitis. JAAD. 2012;66:252-8.
- Mrowietz U, Steinz K. Psoriasis: to treat or to manage? Exp Dermatol. 2014;10:705-9.
- Chernyshov PV. Health related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. G Ital Dermatol Venereol. 2014. Jun 14.
- Bhutani T, Patel T, Koo B. A prospective interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. JAAD. 2013;69:79-88.
- 19. Martinez-Garcia E, Arias-santiago S. Quality of life in persons living with psoriasis patients. JAAD. 2014;71:302-7.
- Phillipp S, Koerber A. Nail and scalp involvement in plaque type psoriasis affects patients' quality of life but can be improved by adequate systemic therapy: A German study. JAAD. 2014:AB176.
- Klaassen KM, Van de Kerkhof PC. Nail Psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28:1690-5.
- Zampieron A, Buja A, Fusco M, Linder D, Bortune M, Piaserico S, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150:309-16.
- Coacioli S, Bruno AA. Validation of an origin questionnaire for patients with psoriatic arthritis: the psoriatic arthritis impact profile (PAIP). Clin Ter. 2014;165:100-8.
- Torre-Alonso JC, Gratacos J. Development and Validation of a New Instrument to Measure Health-related Quality of Life in Patients with Psoriatic Arthritis: The VITACORA-19. J Rheumatol. 2014;41:2008-17.
- 25. Ekelund M, Mallbris L. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients

- with plaque psoriasis. Acta Dermvenereol. 2013;93:684-8.
- Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377-88.
- 27. Tezel N, Yilmaz Tasdelen O, Bodur H, Gul U, Kulcu Cakmak S, Oguz ID, et al. Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone? Int J Rheum Dis. 2015;18:63-9.
- 28. Lin TY, See LC. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186-96.
- **29.** Valenzuela F, Silva P. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr. 2011;102:810-6.
- Hayashi M. Impact of disease severity on work productivity and activity impairment in Japanese patients with psoriasis. J Dermatol Science. 2013;72:183-201.
- Armstrong AW, Schupp C. Quality of life and work productivity impairment among psoriasis patients: findings from the National psoriasis foundation survey data 2003-2011. Plos One. 2012;7:e52935.
- Jankowiak B, Sekmistrz S. Satisfaction with life in a group of psoriatis patients. Post Dermatol Alergol. 2013;2:85-90.
- Miniszewska J, Juczynski Z. Health-related quality of life in psoriasis: important role of personal ressources. Acta Derm Venereol. 2013;93:551-6.
- 34. Darjani A, Heidarzadeh A. Quality of Life in Psoriatic Patients: A Study Using the Short Form-36. Int J Prev Med. 2014;5:1146-52.
- Sanchez-Carazo JL, Lopez-Estebaranz JL. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). J Dermatol. 2014;41:673-8.
- Nyunt WW, Low WY. Determinants of Health-Related Quality of Life in Psoriasis Patients in Malaysia. Asia Pac J Public Health. 2015;27:NP662-73.
- Gupta MA, Gupta AK, Kirkby S, Weiner HK. Pruritus in psoriasis.
   A prospective study of some psychiatric and dermatologic correlates. Arch. Dermatol. 1988;124:1052-7.
- 38. Yosipovitch G, Goon A, Wee J, Chan YH. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73.
- Szepietowski JC, Reich A, Wiśnicka B. Itching in patients suffering from psoriasis. Acta Derm Venereol. 2002;10:10216–221.
- Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: A questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822–6.
- 41. Stinco G, Trevisan G. Pruritus in chronic plaque psoriasis: a questionnaire-based study of 230 Italian patients. Acta Dermatol Venereol 2014;22:122-8.
- 42. Reich A, Hrehorów E, Szepietowski J C. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257–63.
- 43. Lewis-Beck C, Abouzaid S. Analysis of the relationship between psoriasis symptom severity and quality of life,work productivity and activity impairment among patients with moderate -to -severe using structural equation modeling. Patient Pref Adheren. 2013;7:199-205.
- Remröd C, Sjöström K. Pruritus in Psoriasis: A Study of Personality Traits, Depression and Anxiety. Acta Derm Venereol. 2015;95:439-43.
- McDonough E, Avearst R. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41:887-96.
- 46. Bangemann K. Depression and anxiety disorders among psoriasis patients: Protective and exacerbating factors. Hautarzt. 2014;65:1056-61.
- Dominguez PL, Han J. Depression and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013;27:1163-7.
- Bouguéon K, Misery L. Dépression et psoriasis. Ann Dermatol Venerol. 2008;135:254-8.

- Misery L. Dépression et psoriasis. Ann Dermatol Venerol. 2012;139:S53-7.
- Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891-5.
- 51. Gupta MA, Gupta AK. Quality of life of psoriasis patients. J Eur Acad Dermatol Venereal. 2000;14:241-2.
- Dowlatshahi EA, Wakkee M. Increased antidepressant drug exposure in psoriasis patients: a longitudinal population-based cohort study. Actaderm Venereol. 2013;93:544-50.
- 53. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-96.
- Delfino M Jr, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol. 2008;59:439-47.
- Hu SW, Holt EW, Husni ME, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study. Semin Arthritis Rheum. 2010;39:384-97.
- Smitha G, Ogoldblum OM, Vaughn McCall W. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010;63:114-23.
- 57. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners.

- Br J Dermatol. 2007;156:1245-50.
- 58. Moon HS, Mizara A. Psoriasis and psycho-Dermatology. Dermatol Ther (Heidelb). 2013;3:117-30.
- Poot F, Antoine E. A case control study on family dysfunction in patients with alopecia ariata, psoriasis and atopic dermatitis. Acta Derm Venereol. 2011;91:415-21.
- Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259-62.
- 61. Sampona F, Gisondi P. impairment of sexual life in patients with psoriasis. Dermatology. 2007;214:144-50.
- Sarkar S. Psoriasis and Psychiatric Morbidity: a Profile from a Tertiary Care Centre of Eastern India. J Family Med Prim Care. 2014;3:29-32.
- Armstrong AW, Schupp C, Wu J, Bebo B. Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011. PLoS One. 2012;7:e52935.

Copyright by Awatef Kelati, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Source of Support: Nil, Conflict of Interest: None declared.